# US 2025/0152516 A1 · Compressible sodium caprate formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152516 A1
- Document ID: US20250152516A1
- Status: Published application
- Kind: A1
- Application number: 18/840,222
- Filed: 2023-02-21
- Published: 2025-05-15
- Earliest claimed: 2022-02-22
- Assignees: AstraZeneca AB
- Applicants: AstraZeneca AB
- Inventors: Hanna MATIC; Andreas RÅDEVIK
- Web page: https://patentgrep.com/patent/US20250152516A1

## CPC

- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/2095: {Tabletting processes}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/26: Glucagons
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides a method of making an oral tablet comprising mixing a macromolecule with sodium caprate to form a mixture, and compressing the mixture into a tablet, wherein the sodium caprate is Form A. The present disclosure also provides a tablet made by the process provided herein. Also provided is a composition comprising sodium caprate and a macromolecule.

## Claims

### Claim 1

A method of making an oral tablet, the method comprising
a) mixing a macromolecule with sodium caprate to form a mixture;
b) direct compressing the mixture to form a tablet;
wherein the sodium caprate is Form A sodium caprate characterized by a wide-angle X-ray scattering (WAXS) spectrum which includes a peak at a region of 0.1 to 0.15 Å−1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sodium caprate is Form A sodium caprate characterized by a wide-angle X-ray scattering (WAXS) spectrum which includes a peak at 0.12 and 0.23 Å−1.

### Claim 3 (depends on 1, 2)

The method of any one of claim 1 or 2, wherein the sodium caprate is Form A sodium caprate characterized by a small-angle X-ray scattering (SAXS) spectrum which includes a peak at 0.12 and 0.23 Å−1.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the sodium caprate is Form A sodium caprate characterized by a X-ray powder diffraction (XRPD) spectrum which includes a peak at 4° 2θ.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1 to 4, wherein the sodium caprate has a water content of less than about 3.5% as measured by Karl Fischer titration.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1 to 5, wherein the sodium caprate has a water content of less than about 2.0% as determined by Karl Fischer titration

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1 to 6, wherein the sodium caprate has a water content of less than about 1.5% as determined by Karl Fischer titration.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein the sodium caprate of step (a) is sieved or milled to obtain a desired particle size before the direct compression of (b) to form a tablet.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1 to 8, wherein the mixture of step (a) is sieved or milled to obtain a desired particle size before the direct compression of (b) to form a tablet.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1 to 9, wherein the sodium caprate has a particle size ranging from about 35 μm to about 1300 μm before step (b).

### Claim 11 (depends on 10)

The method of claim 10, wherein the sodium caprate has a particle size ranging from about 100 μm to about 850 μm.

### Claim 12 (depends on 11)

The method of claim 11, wherein the sodium caprate has a particle size ranging from about 250 μm to about 750 μm.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1 to 12, wherein after the tablet compression of (b), a coating is formed on the tablet.

### Claim 14

A method of making an oral tablet, the method comprising
a) Wet granulating sodium caprate in a non-aqueous organic solvent to form granules;
b) Drying and milling the granules
c) Mixing the resulting granules with the macromolecules and other excipients
d) Compressing the mixture to form a tablet;
wherein the sodium caprate after step b) is Form A sodium caprate characterized by a wide-angle X-ray scattering (WAXS) spectrum which includes a peak at a region of 0.1 to 0.15 Å−1 and/or by an X-ray powder diffraction (XRPD) spectrum which includes a peak at 4° 2θ.

### Claim 15

A method of making an oral tablet, the method comprising
a) Wet granulating sodium caprate together with other excipients in a non-aqueous organic solvent to form granules;
b) Drying and milling the granules
c) Mixing the resulting granules with the macromolecules and optionally additional excipients; and
d) Compressing the mixture to form a tablet;
wherein the sodium caprate after step b) is Form A sodium caprate characterized by an X-ray powder diffraction (XRPD) spectrum which includes a peak at 4° 2θ.

### Claim 16

A method of making an oral tablet, the method comprising
a) Wet granulating sodium caprate together with a macromolecule and possibly other excipients in a non-aqueous organic solvent to form granules;
b) Drying and milling the granules;
c) Mixing the resulting granules with the other excipients; and
d) Compressing the mixture to form a tablet;
wherein the sodium caprate after step b) is Form A sodium caprate characterized by an X-ray powder diffraction (XRPD) spectrum which includes a peak at 4° 2θ.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1 to 16, wherein the compressing is performed at greater than 10 MPa.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1 to 17, wherein the compressing is performed at 15 MPa to 500 MPa.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1 to 18, wherein the compressing is performed at 25 MPa to 300 MPa.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1 to 19, wherein the compressing is performed at 50 MPa to 200 MPa.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1 to 20, wherein the mixing of (a) further comprises a polyol.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1 to 21, wherein the polyol is chosen from sorbitol, mannitol, maltitol, xylitol and combinations thereof.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1 to 22, wherein the polyol is mannitol.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1 to 23, wherein the macromolecule is about 0.1% to about 12% by weight of the tablet.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 1 to 24, wherein the sodium caprate is about 30% to about 99% by weight of the tablet.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1 to 25, wherein the polyol is about 0.001% to about 50% by weight of the tablet.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1 to 26, wherein the macromolecule is a peptide or an oligonucleotide.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1 to 27, wherein the macromolecule is an oligonucleotide.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 1 to 28, wherein the macromolecule is an oligonucleotide of SEQ ID NO: 1.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1 to 29, wherein the oral tablet has a tablet hardness tensile strength of about 0.5 MPa to about 5 MPa.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1 to 30, wherein the oral tablet has a tablet hardness tensile strength of about 0.75 MPa to about 3 MPa.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1 to 31, wherein the oral tablet has a tablet hardness tensile strength of about 1.0 MPa to about 2.5 MPa.

### Claim 33

A method of making an oral tablet, the method comprising
a) sieving sodium caprate to obtain sodium caprate particles having a particle size of about 35 μm to about 1100 μm
b) mixing the sodium caprate particles with a macromolecule to form a mixture;
c) direct compressing the mixture of to form a tablet;
wherein the sodium caprate is Form A sodium caprate characterized by a wide-angle X-ray scattering (WAXS) spectrum which includes a peak at a region of 0.1 to 0.15 Å−1 and/or by an X-ray powder diffraction (XRPD) spectrum which includes a peak at 4° 2θ and wherein the method does not comprise a wet granulation step, a drying step or a milling step after the mixing of step (a).

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A tablet made by the method of any one of claims 1 to 33.

### Claim 35

A composition comprising a macromolecule and sodium caprate, wherein the sodium caprate is Form A sodium caprate characterized by a wide-angle X-ray scattering (WAXS) spectrum which includes a peak at a region of 0.1 to 0.15 Å−1 and/or by an X-ray powder diffraction (XRPD) spectrum which includes a peak at 4° 2θ.

### Claim 36 (depends on 35)

The composition of claim 35, further comprising a polyol.

### Claim 37 (depends on 36)

The composition of claim 36, wherein the polyol is mannitol.

### Claim 38 (depends on 35, 36, 37)

The composition of any one of claims 35 to 37, wherein the macromolecule is about 0.1% to about 12% by weight of the tablet.

### Claim 39 (depends on 35, 36, 37, 38)

The composition of any one of claims 35 to 38, wherein the sodium caprate is about 30% to about 99% by weight of the tablet.

### Claim 40 (depends on 35, 36, 37, 38, 39)

The composition of any one of claims 35 to 39, wherein the polyol is about 0.001% to about 50% by weight of the tablet.

### Claim 41 (depends on 35, 36, 37, 38, 39, 40)

The composition of any one of claims 35 to 40, wherein the macromolecule is a peptide or an oligonucleotide.

### Claim 42 (depends on 35, 36, 37, 38, 39, 40, 41)

The composition of any one of claims 35 to 41, wherein the macromolecule is an oligonucleotide.

### Claim 43 (depends on 35, 36, 37, 38, 39, 40, 41, 42)

The composition of any one of claims 35 to 42, wherein the macromolecule is an oligonucleotide of SEQ ID NO: 1.

### Claim 44 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The composition of any one of claims 35 to 45, wherein the composition is in the form of an oral tablet, and the oral tablet has a tablet hardness tensile strength of above 0.5 MPa.

### Claim 45 (depends on 44)

The composition of claim 44, wherein the oral tablet has a tablet hardness tensile strength of about 0.5 MPa to about 5 MPa.
